EP
BBNX

Eversept Partners’s Beta Bionics BBNX Stock Holding History

Eversept Partners’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6M Sell
1,249,441
-165,397
-12% -$1.97M 1.02% 28
2026
Q1 		$14.2M Buy
1,414,838
+736,576
+109% +$10.9M 0.75% 34
2025
Q4 		$20.7M Buy
+678,262
New +$18.1M 1.04% 25

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners's BBNX Position: Q2 2026 in Review

Eversept Partners reduced its Beta Bionics (BBNX) stake by 12% in Q2 2026, selling an estimated $1.97M and leaving 1,249,441 shares worth $19.6M. The position accounts for 1.02% of the portfolio, ranked #28.

Eversept Partners first reported a position in BBNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $20.7M in Q4 2025. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Eversept Partners held 1,249,441 shares of Beta Bionics worth $19.6M as of Q2 2026.
  • Eversept Partners sold 165,397 Beta Bionics shares in Q2 2026, an estimated $1.97M.
  • Beta Bionics made up 1.02% of Eversept Partners's portfolio in Q2 2026, its #28 holding.
  • Eversept Partners first reported a position in Beta Bionics in Q4 2025 and has held it in 3 quarters since.
  • Eversept Partners's Beta Bionics position peaked at $20.7M in Q4 2025.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.